



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Aripiprazole hydrate

Paliperidone palmitate

Haloperidol decanoate

Risperidone (injections)

March 27, 2018

Non-proprietary name

Aripiprazole hydrate, paliperidone palmitate, haloperidol decanoate, risperidone (injections)

Safety measure

Precautions should be revised in the package insert.

In the Contraindications section, the following language concerning patients receiving adrenaline or clozapine should be revised (revised language is underlined):

Patients receiving adrenaline (except when adrenaline is used for the emergency treatment of anaphylaxis) or clozapine

In the Contraindications for Co-administration subsection of the Interactions section, the following language concerning adrenaline should be revised (revised language is underlined):

Adrenaline (except when used for the emergency treatment of anaphylaxis)

*Haloperidol decanoate and risperidone (injections) are designated as a drug requiring preparation of a Drug Guide for Patients.

Pharmaceuticals and Medical Devices Agency

Office of Safety I

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan

E-mail: safety.info@pmda.go.jp